Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
Pfizer Inc. President, R&D Christoffel Boshoff had 816 shares of common stock withheld on February 23, 2026 to cover tax obligations upon the vesting of restricted stock units, at a price of $27.06 per share. After this tax-withholding disposition, he directly holds 154,829 shares and indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On the vesting of restricted stock units, 419 shares of common stock were withheld at $27.06 per share to satisfy tax obligations, leaving her with 12,186 directly held shares.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock. On 02/12/2026, he received 2,883 Phantom Stock Units SSP at $27.47 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit represents one phantom share of common stock and is settled in cash after his separation from service. Following this grant, Bourla beneficially owned 757,286 derivative units on a direct basis, providing additional deferred, cash-settled exposure to Pfizer’s share value rather than immediate stock ownership.
Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.
Pfizer Inc filed a Form 13F reporting its institutional holdings. The report lists 21 securities entries with a total reported market value of $236,464,562 as shown on the Form 13F summary page. The filing was signed by Madelyn D. Purcell, Assistant General Counsel on 02-10-2026.
Pfizer Inc. filed a current report to make investors aware that it has released its financial results for the fourth quarter of 2025. The company did this by issuing a press release on February 3, 2026, which is attached to the report as Exhibit 99.
The press release is formally provided for information purposes and is not treated as being legally “filed” under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Pfizer Inc. executive Christoffel Boshoff reported a tax‑related share withholding tied to equity compensation. On January 30, 2026, 12,887 shares of Pfizer common stock were withheld at $26.44 per share to satisfy tax obligations upon vesting of restricted stock units, rather than being an open‑market sale. After this transaction, Boshoff beneficially owned 155,645 shares directly and 698 shares indirectly through a Rule 16b‑3 plan.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of 79 Phantom Stock Units SSP on January 14, 2026 at $25.58 per unit. Each unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. After this transaction, Bourla held 743,136 phantom stock units. These units are settled in cash after his separation from service and can be moved into an alternative investment account at any time, so they function as deferred cash-based compensation rather than actual shares.
Pfizer Inc. director Mortimer J. Buckley reported a deferred compensation transaction involving phantom stock units tied to Pfizer common stock. On 12/31/2025, he acquired 1,506.024 phantom stock units, each representing one phantom share of common stock. These units reflect deferred director compensation, including dividend equivalents, and are designed to be settled in cash or Pfizer common stock at the director’s election after he retires from the Board of Directors. Following this transaction, Buckley beneficially owned a total of 15,078.063 phantom stock units, all held as a direct interest.
Pfizer Inc. director reports additional deferred compensation units
A Pfizer Inc. director reported acquiring 1,857.43 phantom stock units linked to Pfizer common stock on 12/31/2025. Each unit represents one phantom share of common stock. After this transaction, the director beneficially owns 149,314.146 derivative securities in the form of phantom stock units.
These units represent deferred director compensation, including dividend equivalents, that will be settled in either cash or Pfizer common stock at the director’s election after retirement from the Board of Directors.